Lemaitre Vascular (LMAT) Tops Q2 EPS by 6c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
LeMaitre Vascular (LMAT) PT Raised to $32 at Stifel Following 2Q
July 28, 2017 8:42 AM EDTStifel raised its price target on LeMaitre Vascular (NASDAQ: LMAT) to $32.00 (from $29.00) while maintaining a Buy rating. LMAT reported 2Q revenues of $25.8M. Record EPS of $0.23 grew nearly 70% handily beating the consensus projections.
The company raised its full-year revenue forecast above and beyond the... More
